The creation, covered in rose gold, pink and topaz crystals, was plucked from the Australian designer’s fall 2023 couture collection. Lively donned the skin-baring cutout dress with nothing ...

Brighten up your golf wardrobe with this Lilly Pulitzer skort in a vibrant pink hue, offering UPF 50 ... Embrace a breezy vibe with this smocked dress, designed with a lovely print that brings ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may earn compensation through affiliate links within the story. All prices are ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...

Shares of Eli Lilly and Co. slumped toward their biggest selloff in more than three years on Wednesday, after the drugmaker reported third-quarter results that missed expectations, due to big ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

Eli Lilly’s third-quarter sales and earnings were lower than expected, a rare stumble for the company that had consistently reported strong sales and beat earnings forecasts since demand for its ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...